Skip to main content
. Author manuscript; available in PMC: 2023 May 1.
Published in final edited form as: Ann Allergy Asthma Immunol. 2022 Feb 5;128(5):575–582. doi: 10.1016/j.anai.2022.01.043

Figure 4: Outcomes of biologic therapy among AERD patients.

Figure 4:

Most patients who discontinued to a biologic transitioned to a different biologic agent, with 19 patients ultimately being transitioned to dupilumab. Only four patients discontinued biologic therapy entirely.